Hypocalcemia prevention

Hypocalcemia prevention refers to prophylactic clinical measures aimed at avoiding a pathologically low concentration of serum calcium, typically defined as an albumin-corrected total serum calcium below 8.5 mg/dL or an ionized calcium below 4.6 mg/dL This intervention primarily targets vulnerable populations at high risk for electrolyte depletion, such as patients undergoing thyroid or parathyroid surgery, individuals receiving antiresorptive therapies like bisphosphonates or denosumab, and pat...

This intervention primarily targets vulnerable populations at high risk for electrolyte depletion, such as patients undergoing thyroid or parathyroid surgery, individuals receiving antiresorptive therapies like bisphosphonates or denosumab, and patients with chronic kidney disease, hypomagnesemia, or malabsorptive states

This intervention primarily targets vulnerable populations at high risk for electrolyte depletion, such as patients undergoing thyroid or parathyroid surgery, individuals receiving antiresorptive therapies like bisphosphonates or denosumab, and patients with chronic kidney disease, hypomagnesemia, or malabsorptive states

Pathophysiologically, maintaining normal extracellular calcium concentrations prevents dangerous neuromuscular hyperexcitability and cardiac instability, averting clinical manifestations that range from mild paresthesias, tetany, and muscle spasms to life-threatening complications such as laryngospasm, seizures, and QT prolongation